title: Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistula.
abstract: Urotensin II (UTII) is a potent vasoactive peptide. Recent studies have demonstrated increased expression of both UTII and its receptor (UTR) expression in end-stage congestive heart failure (CHF), but it is unclear whether UTII and UTR are late stage markers of decompensation, or earlier adaptive responses. The purpose of this study was to measure the effects of chronic UTII administration in normal and volume overloaded animals. Chronic 4 weeks administration of UTII produced decreases in hemodynamic function in animals not subjected to volume overload while returning function to control levels in animals with overload. Expression levels of calcium regulatory proteins phospholamban (PLN), sarcoplasmic reticulum Ca(2+) ATPase (SERCA2), and Na(+)/Ca(2+) exchanger (NCX) were measured to determine if administration of UTII resulted in aberrant Ca(2+) handling. Changes in protein expression revealed that UTII influenced Ca(2+) handling proteins in normal animals although these changes are not seen in the volume overload.
authors.affiliation: Department of Physiology, The Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA.
authors.forename: Gregory S
authors.initials: GS
authors.lastname: Harris
authors.forename: Robert M
authors.initials: RM
authors.lastname: Lust
authors.forename: Laxmansa C
authors.initials: LC
authors.lastname: Katwa
mesh_terms: D000818:Animals; D001018:Aortic Diseases / Q000503:physiopathology; D001164:Arteriovenous Fistula / Q000235:genetics / Q000503:physiopathology*; D001794:Blood Pressure / Q000187:drug effects; D002135:Calcium-Binding Proteins / Q000378:metabolism; D006333:Heart Failure / Q000235:genetics / Q000503:physiopathology; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D007527:Isoenzymes / Q000378:metabolism; D008297:Male; D018995:Myosin Heavy Chains / Q000235:genetics; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D043562:Receptors, G-Protein-Coupled / Q000235:genetics; D011994:Recombinant Proteins / Q000008:administration & dosage; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases / Q000378:metabolism; D019831:Sodium-Calcium Exchanger / Q000378:metabolism; D014579:Urotensins / Q000008:administration & dosage* / Q000235:genetics / Q000502:physiology; D014684:Venae Cavae; D016277:Ventricular Function, Left / Q000187:drug effects; D054460:rho-Associated Kinases; D000099211:Phospholamban
chemical_list: D002135:Calcium-Binding Proteins; D047908:Intracellular Signaling Peptides and Proteins; D007527:Isoenzymes; D018995:Myosin Heavy Chains; D017346:Protein Serine-Threonine Kinases; D012333:RNA, Messenger; D043562:Receptors, G-Protein-Coupled; D011994:Recombinant Proteins; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases; D019831:Sodium-Calcium Exchanger; D014579:Urotensins; D054460:rho-Associated Kinases; D000099211:Phospholamban; C506948:Atp2a2 protein, rat; C000594638:MYH7 protein, rat; C473142:Uts2r protein, rat; C029677:urotensin II